Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).
NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...
As AbbVie inches toward its big loss of exclusivity for Humira in early 2023, the company will have an important launch to help offset the biosim erosion. AbbVie's Vraylar, already a blockbuster, on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback